Anzeige
Mehr »
Login
Samstag, 24.09.2022 Börsentäglich über 12.000 News von 675 internationalen Medien
Unterschrift! Der große Lichtblick im Marktumfeld…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 ISIN: US09058V1035 Ticker-Symbol: BO1 
Tradegate
23.09.22
13:04 Uhr
12,664 Euro
-0,095
-0,74 %
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,58012,84012:58
12,63212,88423.09.

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.09.BioCryst Pharmaceuticals promotes Sheridan to development chief-
14.09.BioCryst Pharmaceuticals, Inc.: BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer7
06.09.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3
31.08.BIOCRYST PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans2
31.08.BioCryst Pharmaceuticals, Inc.: BioCryst to Present at Upcoming Investor Conferences2
31.08.BioCryst wins FDA's Orphan Drug status for bone disorder therapy2
31.08.BioCryst Pharmaceuticals, Inc.: FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans ...-
26.08.BioCryst's BCX9930 for rare kidney disorder shows promise in early-stage study3
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.08.BioCryst Pharmaceuticals, Inc.: BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in ...4
25.08.US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness-
25.08.BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M1
25.08.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
25.08.BioCryst Pharmaceuticals, Inc.: U.S. Government Exercises Option to Purchase Additional RAPIVAB (peramivir injection) from BioCryst for Pandemic Influenza ...1
23.08.BioCryst (BCRX) Stock: $14 Target And Equal-Weight Rating6
18.08.BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks-
18.08.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) in Saudi Arabia3
09.08.BioCryst resumes enrollment for immune diseases drug; Eagle buys stake in respiratory disease biotech6
05.08.BIOCRYST PHARMACEUTICALS INC - 10-Q, Quarterly Report5
05.08.BioCryst Pharmaceuticals (BCRX) Stock: Why It Surged 23.23%3
04.08.Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today12
Seite:  Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1